Advice

in the absence of a submission from the holder of the marketing authorisation:

apalutamide (Erleada®) is not recommended for use within NHSScotland.

Indication under review: In adult men for the treatment of non-metastatic castration-resistant prostate cancer (NM-CRPC) who are at high risk of developing metastatic disease.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.

Download detailed advice611KB (PDF)

Download

Medicine details

Medicine name:
apalutamide (Erleada)
SMC ID:
SMC2268
Indication:

In adult men for the treatment of non-metastatic castration-resistant prostate cancer (NM-CRPC) who are at high risk of developing metastatic disease.

Pharmaceutical company
Janssen-Cilag Ltd
BNF chapter
Malignant disease and immunosuppression
Submission type
Non submission
Status
Not recommended
Date advice published
10 February 2020